News
Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...
AstraZeneca (AZN) stock in focus as its antibody drug Imfinzi gains EU panel support for treating muscle-invasive bladder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback